IVD Recalls Should Be Viewed As “Norm” Rather Than “Exception” – Gutman
This article was originally published in The Gray Sheet
Executive Summary
Recalls should be viewed as a mechanism to improve quality control systems in companies and laboratories, according to Office of In Vitro Diagnostic Device Evaluation & Safety Director Steve Gutman